High Content Screening Market worth $909.0 Million by 2022
High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022
(firmenpresse) - High Content Screening Market by Product (Cell Imaging & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022
According to the new market research report & Analysis System, Flow Cytometry, Consumable, Software, Service) Application (Primary & Secondary Screening, Toxicity Studies, Target Identification & Validation), End User - Global Forecast to 2022", published by MarketsandMarkets
Don
Early buyers will receive 10% customization on reports.
The factors expected to drive the growth of the market are rising need for cost containment in pharmaceutical R&D, growth in funding for cellular research, and technological advancements in HCS solutions during the forecast period. The increasing number of contract research organizations providing HCS outsourcing services and application of HCS in personalized medicine offer significant growth opportunities in the HCS market. The rising adoption of label-free technologies and growing focus on stem cell analysis are the key trends in the HCS market.
In this report, the market is segmented based on product, application, end user, and region. This report also discusses the key market drivers, restraints, opportunities, and challenges for this market and its submarkets.
In 2016, the instruments segment accounted for the largest share in the HCS market. The large share of this segment is attributed to advanced automation techniques and high prices of HCS instruments. The cell imaging and analysis systems sub-segment accounted for the largest share of the HCS instruments market and is expected to further dominate the market by 2022.
In 2016, the primary & secondary screening segment accounted for the largest share of the high-content screening market, followed by target identification. The primary & secondary screening segment is also projected to register the highest growth during the forecast period. Growth in this segment can be attributed to the presence of a large number of potential drug candidates for target-specific delivery. In addition, in the coming years, the use of HCS in primary screening is expected to increase due to significant improvements in instruments and image acquisition & data analysis software.
In 2016, the pharmaceutical & biotechnology companies segment accounted for the largest share of the high-content screening market, followed by academic & government institutes and contract research organizations. The pharmaceutical & biotechnology companies segment will continue to dominate the market in 2022, with the highest growth rate. Growth in this segment can be attributed to the widespread use of HCS in preclinical and clinical studies in pharmaceutical and biotechnology industries.
Browse
138 - Tables
42 - Figures
166 - Pages
View more detailed TOC (at) https://www.marketsandmarkets.com/Market-Reports/high-content-screening-market-42710391.html
In 2016, North America dominated the global market. High R&D expenditure, the presence of major pharmaceutical market players, and increasing government support are some of the factors driving the growth of the HCS market in this region.
The prominent players in the global high-content screening market are GE Healthcare (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group (Switzerland), BioTek Instruments Inc. (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Yokogawa Electric Corporation (Japan), and Merck Millipore (U.S.).
Request for Free Sample Report (at) http://bit.ly/2C1Lvq1
Browse Adjacent Markets (at) Biotechnology Market Research Reports & Consulting
About MarketsandMarkets
MarketsandMarkets
Our 850 fulltime analyst and SMEs at MarketsandMarkets"Growth Engagement Model ". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets"Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
Email: sales(at)marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/high-content-screening-market.asp
Visit Our Website: https://www.marketsandmarkets.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
Email: sales(at)marketsandmarkets.com
Datum: 08.10.2018 - 14:44 Uhr
Sprache: Deutsch
News-ID 1542284
Anzahl Zeichen: 6672
contact information:
Contact person:
Town:
Phone:
Kategorie:
Healthcare & Medical
Typ of Press Release: Erfolgsprojekt
type of sending: Veröffentlichung
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 428 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"High Content Screening Market worth $909.0 Million by 2022
"
steht unter der journalistisch-redaktionellen Verantwortung von
marketsandmarkets (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
